First Warning Systems Changes Name to Cyrcadia Health


Pioneer in Early Cancer Detection Receives $1 Million in Angel Funding Enabling the Final Stages of Clinical Validation
Reno, Nev. – Sept. 30, 2014 – First Warning Systems, a pioneer in early cancer detection through measuring abnormal circadian cellular changes throughout the body, announced the company is changing its name to Cyrcadia Health, Inc. to better address the company’s breadth of upcoming product releases. The initial focus will be on wearable early breast cancer screening technology.
“Our initial focus will be an ‘Internet of Everthing,’ wearable early breast cancer system which detects abnormal circadian cellular changes over time,” said Rob Royea, president and CEO of Cyrcadia Health. “With our most recent infusion of capital, we are able to take this unique technology into final clinical validation trials in the U.S. starting in November. It is our intention to launch this product into South Asia and Europe in mid-2015 followed by the U.S. after final FDA clinical clearance.”
The company’s wearable, smart phone enabled technology, called the iTBraTM, uses a comfortable data collection device placed under a bra to collect 2-12 hours of breast cell data (dynamic cell chaos). Circadian rhythm-based temperature variances of cell cycles are then measured through a patented process to identify abnormalities at the earliest stages of cellular change, the results of which are transferred through a smart device to a global cancer library and communicated back to the patient and physician.
“We have historically raised $1.9 Million in seed monies for the launch of our upcoming technologies” said Royea. “This additional $1 million investment prepares us well for our upcoming Series A goal of raising $10 million. This most recent important infusion also positions Cyrcadia Health to effectively launch its early breast cancer screening technology to address this disease worldwide.”
Cyrcadia Health’s Singapore business partner, Romesh Kaul, CEO of Advanced Medical Systems, Pte. Ltd. (AMS), has been leading breast diagnostic and therapeutic innovations in South Asia for over 20 years.  His introductions to a team of socially concerned angel investors promoted the latest round of funding, through CIS Agriferts, Pte Ltd and RB Investments Pte, Ltd .
“Singapore adoption of advanced healthcare systems as a regional leader is well known,” said Kaul. “As the location of AMS’s headquarters, it shall serve Cyrcadia Health well and provide the basis for approaching the area’s medical institutions for clinical validations. AMS will work with leading providers for early adoption of Cyrcadia wearable technology throughout the region.”
More than 296,000 women in the U.S. alone are diagnosed with breast cancer annually and approximately 39,000 die from the disease each year, many due to lack of early detection. Contributing factors can be due to dense breast tissue which masks cancer on mammograms for women of all ages, but especially those under 40.
With Cyrcadia Health’s non-compressive, non-irradiative technology, the company’s historical 500 patient trials have shown significant promise in addressing the dense breast tissue population.  With a higher propensity for cancer, and limitations of current imaging standards such as mammography in this difficult to image patient population, Cyrcadia Health’s tissue-agnostic, screening technology could provide a much earlier alert to the state of cancer for this population.
“While all countries have thousands of people suffering from this disease, breast cancer is an epidemic in evolving Asian countries,” said Royea. “We are greatly indebted to our Singapore investors for their foresight and commitment in addressing this serious challenge. With their and others support, our smart device enabled technology will allow a woman to simply wear our technology under her normal garments in the privacy of her own home as a monthly breast cancer screening solution.”

About Advanced Medical Systems Pte, Ltd.

Founded in 1988, Advanced Medical Systems Pte, Ltd, AMS is an established medical devices organization offering innovative. multi-disciplinary solutions for centers of excellence across the Asia Pacific region in Radiology, Neurosciences, Orthopedics & Oncology. AMS is the only organization of its kind to offer a complete range of services required for turnkey facility planning, technology implementation, training, management and finance. Headquartered in the Republic of Singapore, AMS directly serves the Asia/Pacific healthcare markets with operating bases and highly trained personnel in Australia, India, Malaysia and Singapore for advanced imaging and minimally invasive therapy systems and services. For more information visit Advanced Medical Systems at or via Facebook at

About Cyrcadia Health, Inc.

Cyrcadia Health, Inc., founded as First Warning Systems in 2008, is based in Reno, Nev. The company’s product line is a device and software service that detects breast tissue abnormalities leading to health risk assessment and management including early breast cancer identification. Three clinical trials with over 500 participants have achieved proof of concept and superior outcomes when compared to other diagnostic protocols. Cyrcadia Health is planning a final, limited clinical trial and a 510k device classification to validate the fourth generation of the product. The company is preparing to apply for a Euro CE Mark to market in the European Union and Asia Pacific markets, with FDA applications following for the US market. Visit Cyrcadia Health at

# # #

Media Contact:

Laurie Hallwyler
For Cyrcadia Health